Wong Vicky Kwan, Lebwohl Mark G
Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA.
Expert Opin Biol Ther. 2005 Nov;5(11):1505-13. doi: 10.1517/14712598.5.11.1505.
Psoriatic arthritis (PsA) is a chronic spondylarthritis that occurs in approximately 23% of plaque psoriasis sufferers. Traditional treatments for rheumatoid arthritis have been used as the first therapeutic approach to treat this inflammatory disease, which has both joint and skin manifestations. However, due to the inefficiency of current disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs in stopping the progression of the joint disease, biologics have emerged as a hopeful alternative to PsA therapy. Etanercept was the first approved tumour necrosis factor-alpha (TNF-alpha) inhibitor for reducing the signs and symptoms of PsA, as well as preventing the progression of the disease. Etanercept is a fully human, soluble, dimeric fusion protein that has the ability to bind to two molecules of TNF, thereby rendering them biologically inactive. Two clinical trials have demonstrated that etanercept is generally a safe, efficacious and well-tolerated biologic therapy for the treatment of PsA.
银屑病关节炎（PsA）是一种慢性脊柱关节炎，约23%的斑块状银屑病患者会出现该病症。类风湿关节炎的传统治疗方法已被用作治疗这种具有关节和皮肤表现的炎症性疾病的首选治疗方法。然而，由于目前的改善病情抗风湿药物和非甾体抗炎药在阻止关节疾病进展方面效率低下，生物制剂已成为银屑病关节炎治疗的一种有希望的替代方法。依那西普是首个被批准用于减轻银屑病关节炎体征和症状以及预防疾病进展的肿瘤坏死因子-α（TNF-α）抑制剂。依那西普是一种完全人源化的可溶性二聚体融合蛋白，能够结合两个TNF分子，从而使其失去生物活性。两项临床试验表明，依那西普通常是一种安全、有效且耐受性良好的用于治疗银屑病关节炎的生物疗法。
